Mo Z, Tang J, Wu Z, Chen D, Xie D, Wang P
Liver Res. 2025; 5(2):97-101.
PMID: 39959345
PMC: 11791849.
DOI: 10.1016/j.livres.2021.04.001.
Lai B, Luo S, Lai J
Front Immunol. 2024; 15:1489205.
PMID: 39478861
PMC: 11521836.
DOI: 10.3389/fimmu.2024.1489205.
Reddy B, Reddy V, Saier Jr M
Microb Physiol. 2024; 34(1):142-152.
PMID: 38955141
PMC: 11262566.
DOI: 10.1159/000540068.
Korsten P, Tampe B
Int J Mol Sci. 2023; 24(13).
PMID: 37445814
PMC: 10341446.
DOI: 10.3390/ijms241310636.
Gutierrez R, Connolly K, Gross A, Haemel A
JAAD Case Rep. 2023; 37:128-130.
PMID: 37366492
PMC: 10288173.
DOI: 10.1016/j.jdcr.2023.05.028.
Association of interferon-based therapy with risk of autoimmune diseases in patients with chronic hepatitis C virus infection: A population-based Taiwanese cohort study.
Chou S, Yeh H, Lin T, Chang Y, Hsu H, Shen Y
Front Immunol. 2022; 13:992819.
PMID: 36275719
PMC: 9585940.
DOI: 10.3389/fimmu.2022.992819.
Insights Gained and Future Outlook From scRNAseq Studies in Autoimmune Rheumatic Diseases.
Zheng Z, Chang L, Li J, Wu Y, Chen G, Zou L
Front Immunol. 2022; 13:849050.
PMID: 35251048
PMC: 8891165.
DOI: 10.3389/fimmu.2022.849050.
Electrochemical Biosensors for Cytokine Profiling: Recent Advancements and Possibilities in the Near Future.
Dutta N, Lillehoj P, Estrela P, Dutta G
Biosensors (Basel). 2021; 11(3).
PMID: 33806879
PMC: 8004910.
DOI: 10.3390/bios11030094.
Rapid expansion of Treg cells protects from collateral colitis following a viral trigger.
Schorer M, Lambert K, Rakebrandt N, Rost F, Kao K, Yermanos A
Nat Commun. 2020; 11(1):1522.
PMID: 32251280
PMC: 7090079.
DOI: 10.1038/s41467-020-15309-6.
The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus.
Oliveira J, Karrar S, Rainbow D, Pinder C, Clarke P, Rubio Garcia A
Arthritis Res Ther. 2018; 20(1):152.
PMID: 30053827
PMC: 6062988.
DOI: 10.1186/s13075-018-1649-1.
Risk of rheumatoid arthritis in patients with hepatitis C virus infection receiving interferon-based therapy: a retrospective cohort study using the Taiwanese national claims database.
Tung C, Lai N, Li C, Tsai S, Chen Y, Chen Y
BMJ Open. 2018; 8(7):e021747.
PMID: 30037875
PMC: 6059328.
DOI: 10.1136/bmjopen-2018-021747.
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.
Riggs J, Hanna R, Rajan B, Zerrouki K, Karnell J, Sagar D
Lupus Sci Med. 2018; 5(1):e000261.
PMID: 29644082
PMC: 5890856.
DOI: 10.1136/lupus-2018-000261.
A Case of Anti-reticulin Antibody-positivity in Metachronous Double Primary Cancer.
Kim K, Jearn L, Kim T
Ann Lab Med. 2017; 38(1):74-76.
PMID: 29071825
PMC: 5700153.
DOI: 10.3343/alm.2018.38.1.74.
Pristane-induced lupus: considerations on this experimental model.
Freitas E, de Oliveira M, Monticielo O
Clin Rheumatol. 2017; 36(11):2403-2414.
PMID: 28879482
DOI: 10.1007/s10067-017-3811-6.
Transcriptional Repression of IFN Regulatory Factor 7 by MYC Is Critical for Type I IFN Production in Human Plasmacytoid Dendritic Cells.
Kim T, Hong S, Lin Y, Murat E, Joo H, Kim T
J Immunol. 2016; 197(8):3348-3359.
PMID: 27630164
PMC: 5101139.
DOI: 10.4049/jimmunol.1502385.
Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link.
Egiziano G, Bernatsky S, Shah A
Best Pract Res Clin Rheumatol. 2016; 30(1):53-62.
PMID: 27421216
PMC: 4947510.
DOI: 10.1016/j.berh.2016.03.001.
Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus Erythematosus.
Stypinska B, Paradowska-Gorycka A
Int J Mol Sci. 2015; 16(10):24194-218.
PMID: 26473848
PMC: 4632746.
DOI: 10.3390/ijms161024194.
Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening.
Shah A, Casciola-Rosen L
Curr Opin Rheumatol. 2015; 27(6):563-70.
PMID: 26352736
PMC: 4643720.
DOI: 10.1097/BOR.0000000000000222.
Adalimumab-induced lupus serositis.
Kelly D, OConnell O, Henry M
BMJ Case Rep. 2015; 2015.
PMID: 25739794
PMC: 4368974.
DOI: 10.1136/bcr-2014-207323.
Deficiency in either 4E-BP1 or 4E-BP2 augments innate antiviral immune responses.
Nehdi A, Sean P, Linares I, Colina R, Jaramillo M, Alain T
PLoS One. 2014; 9(12):e114854.
PMID: 25531441
PMC: 4273997.
DOI: 10.1371/journal.pone.0114854.
